📣 VC round data is live. Check it out!
- Public Comps
- Convatec Group
Convatec Group Valuation Multiples
Discover Convatec Group's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Renishaw, Hamamatsu Photonics, Snibe, Bausch + Lomb and more.
Convatec Group Overview
About Convatec Group
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
Founded
2016
HQ

Employees
10.5K
Website
Financials (LTM)
EV
$7B
Valuation Multiples
Start free trialConvatec Group Financials
Convatec Group reported last 12-month revenue of $2B and EBITDA of $665M.
In the same LTM period, Convatec Group generated $2B in gross profit, $665M in EBITDA, and $374M in net income.
Revenue (LTM)
Convatec Group P&L
In the most recent fiscal year, Convatec Group reported revenue of $2B and EBITDA of $646M.
Convatec Group is profitable as of last fiscal year, with gross margin of 56%, EBITDA margin of 26%, and net margin of 15%.
Financial data powered by Morningstar, Inc.
Convatec Group Stock Performance
Convatec Group has current market cap of $5B, and enterprise value of $7B.
Market Cap Evolution
Convatec Group's stock price is $2.61.
Convatec Group share price decreased by 4.0% in the last 30 days, and by 32.2% in the last year.
Convatec Group has an EPS (earnings per share) of $0.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7B | $5B | -4.0% | -4.0% | -10.7% | -32.2% | $0.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialConvatec Group Valuation Multiples
Convatec Group trades at 2.6x EV/Revenue multiple, and 9.8x EV/EBITDA.
EV / Revenue (LTM)
Convatec Group Financial Valuation Multiples
As of June 4, 2026, Convatec Group has market cap of $5B and EV of $7B.
Convatec Group has a P/E ratio of 13.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Convatec Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Convatec Group Margins & Growth Rates
Convatec Group grew revenue by 5% and EBITDA by 7% in the last fiscal year.
In the most recent fiscal year, Convatec Group reported gross margin of 56%, EBITDA margin of 26%, and net margin of 15%.
Convatec Group Margins
Convatec Group Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Convatec Group Operational KPIs
Convatec Group's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Convatec Group's Rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Convatec Group's Rule of X is 40% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Convatec Group Competitors
Convatec Group competitors include Renishaw, Hamamatsu Photonics, Snibe, Bausch + Lomb, Andon Health, Getinge, Canon Marketing Japan, Caris Life Sciences, Teleflex and Sysmex.
Most Convatec Group public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 5.1x | 4.7x | 22.8x | 20.8x | |||
| 3.6x | 3.5x | 17.8x | 17.7x | |||
| 7.2x | 6.9x | 16.1x | 15.7x | |||
| 2.0x | 1.9x | 11.4x | 10.7x | |||
| 25.2x | - | 12.7x | - | |||
| 1.6x | 1.6x | 8.6x | 8.6x | |||
| 0.9x | 0.9x | 8.2x | 8.2x | |||
| 5.3x | 4.8x | 31.0x | 29.5x | |||
This data is available for Pro users. Sign up to see all Convatec Group competitors and their valuation data. Start Free Trial | ||||||
Convatec Group VC Funding History
Before going public, Convatec Group raised $2B in total equity funding, across 2 rounds.
Last private valuation of Convatec Group was $34B, after raising $1B in March 2017 from Novo Holdings.
Convatec Group Funding Rounds
Acquisitions by Convatec Group
Convatec Group has acquired 5 companies to date.
Last acquisition by Convatec Group was on April 19th 2023. Convatec Group acquired 30 Technology for $57M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Convatec Group
| Description | 30 Technology is a biopharmaceutical platform company developing nitric oxide-based therapies for serious medical conditions. Its technology enables new care models enhancing patient healing and immune responses. The firm partners with healthcare providers to advance treatments for cardiovascular and respiratory diseases. | Triad Life Sciences is a San Diego-based biotechnology company advancing regenerative medicine through bioactive extracellular matrix (ECM) biomaterials. Their proprietary ECM platforms support wound healing, orthopedics, and cardiovascular applications, derived from decellularized porcine tissues. With leadership holding patents from companies like Integra LifeSciences, Triad Life Sciences collaborates with UC San Diego for preclinical trials. Launched in 2020, the firm raised Series A funding to scale manufacturing under ISO 13485 standards. | J&R Medical is a nationwide distributor of urological, enteral feeding, incontinence, and ostomy supplies to hospitals, long-term care facilities, and home care patients across the United States. The company offers products from brands like Hollister, Coloplast, and Medline, with direct delivery options and customized ordering for various price points. | Woodbury Health Products is a Wilmington, North Carolina-based distributor of incontinence solutions, operating from its dedicated facility for nearly 35 years. The company supplies absorbent products, protective undergarments, and hygiene aids to individuals, families, and caregivers across the United States, emphasizing discreet and effective management of urinary health issues. | |
| HQ Country | |||||
| HQ City | - | Memphis, TN | Oklahoma City, OK | New York City, NY | |
| Deal Date | 19 Apr 2023 | 28 Jan 2022 | 2 Mar 2018 | 20 Jul 2017 | |
| Valuation | $57M | $450M | $14M | $121M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Convatec Group acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Convatec Group
Convatec Group has invested in 1 company to date.
Latest investment by Convatec Group was on May 9th 2022. Convatec Group invested in BlueWind Medical in their $64M Series B round (EV/Revenue multiple available to Pro users).
Latest Investments by Convatec Group
| Description | BlueWind Medical is a medtech company marketing the Revi wireless neurostimulation system for chronic peripheral neuropathic pain in the lower limbs. The implantable device delivers on-demand electrical pulses via a coin-sized stimulator placed near the nerve, avoiding bulky hardware. Approved in Europe in 2021, it entered U.S. pivotal trials targeting over 20 million patients. Based in Herzliya, Israel, BlueWind Medical raised $75 million in funding and partners with Boston Scientific for distribution. |
| HQ Country | |
| HQ City | Herzliya |
| Deal Date | 9 May 2022 |
| Round | Series B |
| Raised | $64M |
| Investors | Convatec Group |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Convatec Group investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Convatec Group
| When was Convatec Group founded? | Convatec Group was founded in 2016. |
| Where is Convatec Group headquartered? | Convatec Group is headquartered in United Kingdom. |
| How many employees does Convatec Group have? | As of today, Convatec Group has over 10K employees. |
| Is Convatec Group publicly listed? | Yes, Convatec Group is a public company listed on London Stock Exchange. |
| What is the stock symbol of Convatec Group? | Convatec Group trades under CTEC ticker. |
| When did Convatec Group go public? | Convatec Group went public in 2016. |
| Who are competitors of Convatec Group? | Convatec Group main competitors include Renishaw, Hamamatsu Photonics, Snibe, Bausch + Lomb, Andon Health, Getinge, Canon Marketing Japan, Caris Life Sciences, Teleflex, Sysmex. |
| What is the current market cap of Convatec Group? | Convatec Group's current market cap is $5B. |
| What is the current revenue of Convatec Group? | Convatec Group's last 12 months revenue is $2B. |
| What is the current revenue growth of Convatec Group? | Convatec Group revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Convatec Group? | Current revenue multiple of Convatec Group is 2.6x. |
| What is the current EBITDA of Convatec Group? | Convatec Group's last 12 months EBITDA is $665M. |
| What is Convatec Group's EBITDA margin? | Convatec Group's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Convatec Group? | Current EBITDA multiple of Convatec Group is 9.8x. |
| What is the current FCF of Convatec Group? | Convatec Group's last 12 months FCF is $257M. |
| What is Convatec Group's FCF margin? | Convatec Group's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Convatec Group? | Current FCF multiple of Convatec Group is 25.5x. |
| How many companies Convatec Group has acquired to date? | As of June 2026, Convatec Group has acquired 5 companies. |
| What was the largest acquisition by Convatec Group? | $450M acquisition of Triad Life Sciences on 28th January 2022 was the largest M&A Convatec Group has done to date. |
| What companies Convatec Group acquired? | Convatec Group acquired Triad Life Sciences, Woodbury Health Products, 30 Technology, EuroTec, and J&R Medical. |
| In how many companies Convatec Group has invested to date? | As of June 2026, Convatec Group has invested in 1 company. |
| What was the last Convatec Group investment? | On 9th May 2022 Convatec Group invested in BlueWind Medical, participating in a $64M Series B round. |
| In what companies Convatec Group invested in? | Convatec Group invested in BlueWind Medical. |
See public comps similar to Convatec Group
Lists including Convatec Group
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


